Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Gavras

Showing results (1-10 of 312) with videos related to

Pageof 32
Sort By:
Hypertension (Dallas, Tex. : 1979)|November 1, 1990
Pressor systems in hypertension and congestive heart failure. Role of vasopressinH Gavras
Journal of the American College of Cardiology|February 1, 1983
Hypertension and congestive heart failure: benefits of converting enzyme inhibition (captopril)H Gavras
Hypertension (Dallas, Tex. : 1979)|June 1, 1994
Corcoran Lecture. Angiotensin-converting enzyme inhibition and the heartH Gavras
American Journal of Hypertension|March 11, 2000
Update on the clinical pharmacology of candesartan cilexetilH Gavras
The New England Journal of Medicine|December 8, 1988
The place of angiotensin-converting enzyme inhibition in the treatment of cardiovascular diseasesH Gavras
Blood Pressure. Supplement|January 1, 1997
Angiotensin II antagonism: a new avenue of hypertension managementH Gavras
Clinical and Experimental Hypertension. Part A, Theory and Practice|January 1, 1982
Possible mechanisms of sodium-dependent hypertension: volume expansion or vasoconstriction?H Gavras
Drugs|January 1, 1990
Angiotensin-converting enzyme inhibitors or calcium channel blockers? An overviewH Gavras
Journal of the American Society of Nephrology : JASN|April 14, 1999
Historical evolution of angiotensin II receptor blockers: therapeutic advantagesH Gavras
Circulation|January 1, 1990
Angiotensin converting enzyme inhibition and its impact on cardiovascular diseaseH Gavras
Pageof 32

Showing results (1-10 of 312) with videos related to

Sort By:
Pageof 32
Hypertension (Dallas, Tex. : 1979)|November 1, 1990
Pressor systems in hypertension and congestive heart failure. Role of vasopressinH Gavras
Journal of the American College of Cardiology|February 1, 1983
Hypertension and congestive heart failure: benefits of converting enzyme inhibition (captopril)H Gavras
Hypertension (Dallas, Tex. : 1979)|June 1, 1994
Corcoran Lecture. Angiotensin-converting enzyme inhibition and the heartH Gavras
American Journal of Hypertension|March 11, 2000
Update on the clinical pharmacology of candesartan cilexetilH Gavras
The New England Journal of Medicine|December 8, 1988
The place of angiotensin-converting enzyme inhibition in the treatment of cardiovascular diseasesH Gavras
Blood Pressure. Supplement|January 1, 1997
Angiotensin II antagonism: a new avenue of hypertension managementH Gavras
Clinical and Experimental Hypertension. Part A, Theory and Practice|January 1, 1982
Possible mechanisms of sodium-dependent hypertension: volume expansion or vasoconstriction?H Gavras
Drugs|January 1, 1990
Angiotensin-converting enzyme inhibitors or calcium channel blockers? An overviewH Gavras
Journal of the American Society of Nephrology : JASN|April 14, 1999
Historical evolution of angiotensin II receptor blockers: therapeutic advantagesH Gavras
Circulation|January 1, 1990
Angiotensin converting enzyme inhibition and its impact on cardiovascular diseaseH Gavras
Pageof 32